Susquehanna International Group
CRDL

Susquehanna International Group’s Cardiol Therapeutics CRDL Stock Holding History

Susquehanna International Group’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-133,000
Closed -$269K – 12121
2024
Q2 		$269K Buy
133,000
+95,000
+250% +$202K ﹤0.01% 9693
2024
Q1 		$68.8K Buy
38,000
+20,600
+118% +$27.8K ﹤0.01% 11422
2023
Q4 		$14.6K Buy
+17,400
New +$14.8K ﹤0.01% 12022
2022
Q2 		– Sell
-87,000
Closed -$134K – 13015
2022
Q1 		$134K Sell
87,000
-30,300
-26% -$50K ﹤0.01% 11663
2021
Q4 		$217K Buy
+117,300
New +$324K ﹤0.01% 11266

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's CRDL Position: Q1 2026 in Review

Susquehanna International Group reduced its Cardiol Therapeutics (CRDL) stake by 65% in Q1 2026, selling an estimated $137K and leaving 70,396 shares worth $95K. The position accounts for ﹤0.01% of the portfolio, ranked #12372.

Susquehanna International Group first reported a position in CRDL in Q1 2022 and has held it in 13 quarters since. The position peaked at $194K in Q4 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Susquehanna International Group held 70,396 shares of Cardiol Therapeutics worth $95K as of Q1 2026.
  • Susquehanna International Group sold 133,330 Cardiol Therapeutics shares in Q1 2026, an estimated $137K.
  • Cardiol Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12372 holding.
  • Susquehanna International Group first reported a position in Cardiol Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • Susquehanna International Group's Cardiol Therapeutics position peaked at $194K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.